Steven Gillis - 14 Jun 2023 Form 4 Insider Report for Homology Medicines, Inc. (QTTB)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
15 Jun 2023, 19:25:26 UTC
Prior SEC filing
21 Feb 2023
Next SEC filing
18 Jul 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Paul Alloway, Attorney-in-Fact for Steven Gillis

Key filing fact

Steven Gillis filed Form 4 for Homology Medicines, Inc. (QTTB) on 15 Jun 2023.

Key facts

  • This page summarizes Steven Gillis's Form 4 filing for Homology Medicines, Inc. (QTTB).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 15 Jun 2023, 19:25.

Change

  • Previous filing in this sequence was filed on 21 Feb 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FIXX transaction Derivative

Option (Right to Buy)

Award

Transaction value
$0
Shares
+23,000
Change %
Price
$0.000000
Shares after
23,000
Date
14 Jun 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
23,000
Exercise price
$1.03
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .